Tamara Gray

Dr

  • 506 Citations
  • 10 h-Index
20052019
If you made any changes in Pure these will be visible here soon.

Personal profile

Public Profile

Currently I am working as the Precision Medicine Theme Research Manager where I am integrally involved in the reporting of research projects to government and private funding bodies. As part of this role I also aid in grant applications and coordinate collaborations between our scientists and other medical research colleagues and commercial partners. 

Previously I worked as a team leading post-doctoral researcher within the group, where my focus was on the long term drug free survival of CML patients successfully treated with tyrosine kinase therapy. While many patients are cured of their disease (where cure is no detectable leukaemia) whilst on therapy, 70% of these patients will have a rapid relapse of disease when therapy is ceased. The over-reaching aim of this study is to determine what factors affect a patient’s ability to achieve treatment free remission (TFR; no detectable leukaemia when off therapy). Maximising a patient’s ability to achieve TFR, by understanding their basic biology, will allow for more patients to cease therapy and therefore improve their long-term quality of life and clinical outcome.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2005 2019

  • 506 Citations
  • 10 h-Index
  • 10 Article
  • 5 Letter
  • 1 Chapter
  • 1 Review article

Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia

Ross, D. M., Pagani, I., Irani, Y., Clarson, J., Gray, T., Dang, Y., McLean, J., Saunders, V., Carne, L., Reynolds, J., Ritchie, D. S., White, D., Branford, S., Hughes, T. & Yong, A., 1 Aug 2019, In : British Journal of Haematology. 186, 3, p. e56-e60

Research output: Contribution to journalLetter

2 Citations (Scopus)

Modelling predictors of molecular response to frontline imatinib for patients with chronic myeloid leukaemia

Banjar, H., Ranasinghe, D., Brown, F., Adelson, D., Kroger, T., Gray, T., White, D., Hughes, T. & Chaudhri, N., 1 Jan 2017, In : PLoS ONE. 12, 1, e0168947.

Research output: Contribution to journalArticle

15 Citations (Scopus)

An oncogenic role for sphingosine kinase 2

Neubauer, H. A., Pham, D. H., Zebol, J. R., Moretti, P. A. B., Peterson, A. L., Leclercq, T. M., Chan, H., Powell, J. A., Pitman, M. R., Samuel, M. S., Bonder, C. S., Creek, D. J., Gliddon, B. L. & Pitson, S. M., 1 Jan 2016, In : Oncotarget. 7, 40, p. 64886-64899 14 p.

Research output: Contribution to journalArticle

10 Citations (Scopus)

Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells

Lu, L., Saunders, V. A., Leclercq, T. M., Hughes, T. P. & White, D. L., 7 Aug 2015, In : Leukemia. 29, 8, p. 1792-1794 3 p.

Research output: Contribution to journalLetter